The purpose of this study is to gain a greater understanding of cancer survivors' attitudes, perspectives, and concerns about medical cannabinoids (MCs) for cancer symptom and side effect management. Using qualitative methods, we conducted four focus groups (n = 19) with cancer survivors recruited from a community-based cancer wellness center. Groups were audio-recorded and facilitated by experienced co-moderators who directed discussion using a semi-structured interview guide. Transcripts were coded using principles from Grounded Theory. Analyses revealed the following ten themes and percentages of codes applied: 1) Attitudes & Beliefs (25.3%), 2) Access (17.1%), 3) Information (15.5%), 4) Concern (14%), 5) How MCs Helped (12.6%), 6) Comfort (4.3%), 7) Confusion (3.6%), 8) Trust/Distrust (3.1%), 9) Behaviors (2.3%), and 10) Support (2.2%). Participants reported that MCs offer potential benefits for symptom management and side effect relief, especially in reducing and managing pain. Despite the growing number of states that are legalizing MCs, significant barriers exist that make knowledge and adequate access a challenge for many.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ctim.2019.102204 | DOI Listing |
Asian Pac J Cancer Prev
January 2025
Department of Physics, Faculty of Sciences, Arak University, Arak, Iran.
Objective: Addressing the rising cancer rates through timely diagnosis and treatment is crucial. Additionally, cancer survivors need to understand the potential risk of developing secondary cancer (SC), which can be influenced by several factors including treatment modalities, lifestyle choices, and habits such as smoking and alcohol consumption. This study aims to establish a novel relationship using linear regression models between dose and the risk of SC, comparing different prediction methods for lung, colon, and breast cancer.
View Article and Find Full Text PDFJNCI Cancer Spectr
January 2025
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC.
Methods: Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included.
Cancer Med
February 2025
Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Chiba, Japan.
Background: Due to its rarity, there are very limited data available on the cause of death (COD) and its association with comorbidities in Japanese chronic lymphocytic leukemia (CLL) patients.
Methods: To investigate the prevalence of comorbidities and their impact on cause-specific mortality, we retrospectively reviewed 121 Japanese patients with CLL.
Results: The median age was 69 years, with 47.
BMC Med Res Methodol
January 2025
Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, 3180 Porter Drive, Office 118, Stanford, CA, 94304, USA.
Background: To effectively monitor long-term outcomes among cancer patients, it is critical to accurately assess patients' dynamic prognosis, which often involves utilizing multiple data sources (e.g., tumor registries, treatment histories, and patient-reported outcomes).
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!